ARS Pharmaceuticals Submits Response to FDA Complete Respons

Response addresses all additional requests in FDA CRL, including positive data from a repeat dose PK/PD study of neffy under nasal allergen challenge (NAC) conditions, and updated testing that detected

Related Keywords

United States , Richard Lowenthal , Laura Oneill , Justin Chakma , Pharmaceuticals Inc , Nasdaq , Advisory Committee , Drug Administration , Exchange Commission , New Drug Application , Complete Response Letter , Typei Allergic Reactions , Private Securities Litigation Reform Act , Annual Report , Region ,